The identification of target structures is a prerequisite for the development of new treatment options, like antibody based therapy, against methicillin resistant Staphylococcus aureus (MRSA). In this study we identified immunodominant structures which were expressed in vivo during sepsis caused by MRSA. Using human sera we compared the immune response of humans with MRSA sepsis with the immune response of normal individuals and asymptomatically colonized individuals. We identified and characterized four staphylococcal specific antigenic structures. One target is a staphylococcal protein of 29 kDa that exhibited 29% identity to secreted protein SceA precursor of Staphylococcus carnosus. The putative function of this protein, which was designated IsaA (immunodominant staphylococcal antigen), is unknown. The second target is an immunodominant protein of 17 kDa that showed no homology to any currently known protein. This immunodominant protein was designated IsaB. The third and fourth antigens are both immunodominant proteins of 10 kDa. One of these proteins showed 100% identity to major cold shock protein CspA of S. aureus and the other protein was identified as the phosphocarrier protein Hpr of S. aureus. The identified immunodominant proteins may serve as potential targets for the development of antibody based therapy against MRSA. ß
Introduction
Staphylococcus aureus is the most common cause of nosocomial infections with a signi¢cant morbidity and mortality [1^3] . The percentage of staphylococcal strains exhibiting wide-spectrum resistance to antibiotics, such as methicillin resistant S. aureus (MRSA), has become increasingly prevalent since the 1980s [3, 4] , posing a threat for e¡ective antimicrobial therapy. In addition, the recent emergence of vancomycin resistant S. aureus strains has aroused the fear that MRSA strains will emerge and spread for which no e¡ective therapy is available [5, 6] . Therefore, alternative treatment options are urgently required to combat infections by this common pathogen. Infections caused by MRSA are seen more often in intensive care units due to the immunocompromised state of many patients [7] . Taking this into account, antibody therapy should be considered as a new treatment option to overcome directly the immunocompromised state of the patients.
Potential targets for monoclonal antibodies are products of staphylococcal genes activated during in vivo infections. Several S. aureus virulence factors and bacterial components have been identi¢ed. Cell wall components and toxin products, such as type 5 and 8 capsular polysaccharides, and exotoxins are known targets of the host immune response. In addition, the presence of opsonizing antibodies against these targets facilitating phagocytosis in vitro was described [8^11] . The role of serotype 5 capsular polysaccharide for immune response and virulence of S. aureus in a mouse model has also been addressed [12] . Other inves-tigations were focused on humoral immune response to S. aureus components, such as peptidoglycan or teichoic acid [13^15] . The reported overlap in the range of antibody titers between infected patients and healthy individuals limits the clinical usefulness of such bacterial factors [16] . Also, the role of humoral antibody response to S. aureus virulence factors, such as K:-toxin and enterotoxins, is less certain, since the titer of antistaphylococcal antibodies does not correlate with severity of infection [17^19] .
More recently, in a mouse model of renal infection, protective e¤cacy against S. aureus infection after active immunization with a novel in vivo expressed polysaccharide antigen (poly-N-succinyl L-1^6 glucosamine), which is distinct from the type 5 and 8 capsular polysaccharides, could be shown [20] . However, the protective capacity of antibodies raised against this polysaccharide antigen in human infections by S. aureus has not been de¢ned yet. Despite promising candidates for a vaccine including the capsular polysaccharides 5 and 8, native and recombinant fragments of S. aureus protein adhesins for host extracellular matrix proteins [21] and proteins involved in global control of virulence factors [22] , a vaccine for S. aureus has not been developed yet. Therefore, alternative target structures for immunotherapy should be explored.
In the present study, we have adopted an approach for isolating MRSA cell structures and protective epitopes based on their antigenicity during human infection.
Materials and methods

Patients and serum samples
We have investigated the antibody response in sera of 23 individuals (Table 1) . Between 1997 and 1998, ¢ve patients admitted to the surgical intensive care unit developed nosocomial sepsis caused by MRSA. The mean ( þ S.D.) age of septic patients was 59 ( þ 16) years. Sepsis was de¢ned according to the Bone criteria [23] . Serum samples were obtained several times during the course of sepsis. As controls, sera of 15 healthy individuals and sera of three individuals colonized with MRSA without any signs of infection were used. The mean ( þ S.D.) age of healthy donors was 61 ( þ 19) years. The mean ( þ S.D.) age of colonized individuals was 48 ( þ 17) years. All sera were collected by venipuncture and were stored at 320³C.
Strains
The MRSA strains used in this study are listed in Table  2 . All MRSA strains were clinical isolates from septic patients. Staphylococcus carnosus strain TM300 and Staphylococcus epidermidis strain RP62A were employed for control purposes. Escherichia coli XL1-Blue subcloning-grade competent cells, E. coli BL21(DE3) and pCALn-EK vector were purchased from Stratagene (La Jolla, CA, USA). 
Bacterial cultivation and DNA puri¢cation
MRSA strains were routinely grown at 37³C on LBagar or in LB-broth. E. coli strains were grown at 37³C on LB-agar or in LB-broth supplemented with 50 Wg ml 31 of carbenicillin and 34 Wg ml 31 of chloramphenicol. Genomic DNA was isolated as described elsewhere [24] . Isolation of plasmid DNA was carried out by using a QIAprep plasmid kit (Qiagen, Hilden, Germany).
Pulsed-¢eld gel electrophoresis (PFGE)
For PFGE of MRSA strains the protocol described previously was used [25] .
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS^PAGE)
A modi¢ed version of the SDS^PAGE technique by Laemmli [26] was carried out.
For specimen preparation, MRSA overnight cultures (2 ml) were pelleted and resuspended in 100 Wl protease inhibitor bu¡er (one protease inhibitor tablet (Boehringer, Mannheim, Germany), 50 mM Tris^HCl (pH 7.5), 2 mM EDTA) and 25 Wl Laemmli bu¡er (SDS 11% w/v, 2-mercaptoethanol 11% v/v, glycerol 10% v/v and 0.05 M TrisĤ Cl, pH 6.8). Specimens were boiled for 10 min, centrifuged for 2 min at 9500Ug and 10 Wl of supernatants with soluble proteins were subsequently applied to wells in a 6% acrylamide stacking gel over a separating gel of 10% or 15% acrylamide. Gels were run in a mini-Protean II chamber (Bio-Rad Laboratories, Richmond, CA, USA). Separated proteins were stained with Coomassie blue (50 mg in 25 ml methanol, 25 ml water, 6.25 ml acetic acid).
Immunoblot (Western blot)
For immunoblot experiments, separated proteins were transferred to nitrocellulose sheets (0.45 Wm pore size, Schleicher and Schuell, Dassel, Germany) by semidry electroblotting in a graphite chamber as previously described [27] . Nonspeci¢c binding sites were saturated with 5% non-fat dry milk (Bio-Rad Laboratories, Richmond, CA, USA) in phosphate-bu¡ered saline (PBS), pH 7.4. The nitrocellulose sheets were incubated with human sera (diluted 1:400) for 1 h. Incubated sheets were washed with PBS^0.05% Tween 20 and bound antibodies were detected with a horseradish peroxidase conjugated anti-human IgM, IgG, IgA secondary antibody (Dako, Hamburg, Germany; diluted 1:1000). Blots were developed with SuperSignal 0 Substrate (Pierce, Rockford, IL, USA).
N-terminal amino acid sequence analysis
For N-terminal amino acid sequencing, staphylococcal whole cell extract with soluble proteins was concentrated as described by Wessel and Flugge [28] and Tricine-SDSP AGE was performed as described by Scha «gger and Jagow [29] , using 10% or 15% separating gels.
Subsequently, gels were blotted onto polyvinylidene di£uoride membrane, using a transfer bu¡er system (35 mM CAPS, 0.7 mM 3 MPS (pH 10.0), 30% methanol, 0.1% SDS) and membranes were stained with Coomassie blue. Detected immunodominant proteins were excised from the membrane and resulting protein spots were installed in the blot cartridge of a model ABI 473 amino acid analyzer (Applied Biosystems, Foster City, CA, USA).
DNA sequence analysis of immunodominant proteins
The detected N-terminal amino acid sequences of immunodominant proteins were compared with known amino acid sequences of various protein databanks. In addition, N-terminal amino acid sequences without any Blast search result were compared with data of un¢nished S. aureus genome sequencing [30] . Large contigs, which include sequences that matched 100% with the predicted N-terminal amino acid sequence of immunodominant proteins, were analyzed for open reading frames (ORFs) using ORF Finder at the National Center for Biotechnology Information (NCBI). ORFs, where the presumed molecular mass of the protein product was similar to the molecular mass of immunodominant protein determined by immunoblotting, were cloned in pGEM-Teasy (Promega Escherichia coli and subsequently sequenced using a DNA sequencer model LI-COR 4000 according to the manufacturer's instructions (LI-COR, Lincoln, NE, USA).
Ligation independent cloning (LIC), protein overexpression and puri¢cation
For immunodominant protein overexpression and puri¢cation A¤nity1 LIC cloning and protein puri¢cation kit (Stratagene, La Jolla, CA, USA) was used. The LIC method was carried out according to the manufacturer's instructions and was used to clone the coding sequence of immunodominant proteins into the pCAL-n-EK vector that allows the fusion of the calmodulin binding peptide (CBP) puri¢cation tag (molecular mass 4 kDa) and enterokinase (EK) cleavage site to the N-terminus of the protein coding sequence.
PCR primers were designed containing a pCAL-n-EK speci¢c sequence followed by speci¢c protein coding sequence with a length of 21 bp, 5P-GAC GAC GAC AAG (X 21 (protein sequence))-3P (sense) and 5P-GGA ACA AGA CCC GT (X 21 (protein sequence))-3P (antisense). The PCR products were treated with Pfu polymerase and after Pfu treatment, the protein coding sequence was annealed to the vector at room temperature without any further enzymatic treatment. The annealed product was subcloned in XL1-blue competent cells and transformed to expression strain BL21(DE3). Overexpression of immunodominant proteins were induced with isopropyl-1-thio-L-D-galactopyranoside and analyzed by Coomassie blue stained SDS^PAGE. After preparation of protein extract, puri¢cation of protein with calmodulin (CaM) a¤nity resin was performed. The CBP tag of the fusion protein has high a¤nity for the immobilized protein CaM. Immobilization and conformational change of CaM occurs in the presence of calcium containing bu¡er. Finally, the CBP tag of puri¢ed fusion protein was removed by cleavage with EK at the EK target sequence. Antigenâ ntibody interaction could be veri¢ed by immunoblot on overexpressed and puri¢ed immunodominant proteins.
Enzyme linked immunosorbent assay (ELISA)
Four overexpressed and puri¢ed immunodominant proteins were diluted (1 Wg ml 31 ) in coating bu¡er (0.2 M sodium carbonate, pH 9.4^9.7). 96 well microtitration plates were coated with 100 Wl of this preparation. Following overnight incubation at 4³C, the plate was washed three times with PBS^0.05% Tween 20. 100 Wl of serum (diluted 1:1000) was added to each well and the plate was incubated at room temperature for 1 h. Following washing as above, horseradish peroxidase conjugated anti-human IgM, IgG, IgA antibody (Dako, Hamburg, Germany) was diluted 1:1000 in 5% non-fat dry milk (Bio-Rad Laboratories, Richmond, CA, USA) in PBS, pH 7.4 and 100 Wl was added to each well.
The plate was incubated at room temperature for 1 h and following washing with 100 Wl of rinsing bu¡er, a solution of horseradish peroxidase substrate (0.1 M sodium acetate (pH 4.2), 0.05 sodium dihydrogen phosphate, 4 mM 2,2P-acino-di(3-ethylbenzthiazolinesulfonic acid, 2.5 mM hydrogen peroxide) was added to each well. After 45 min the optical density was measured at 405 nm on an ELISA plate reader (Bio-Rad Laboratories, Richmond, CA, USA). Controls were (1) coating bu¡er and (2) dilution bu¡er.
Results
Typing of MRSA strains belonging to de¢nite clonal groups
In Germany, MRSA isolates from the majority of outbreaks of nosocomial infections can be di¡erentiated into six clonal groups by PFGE [31] . The clonal group of MRSA strains used in this study was therefore determined by PFGE. Each MRSA isolate exhibited a characteristic pattern in PFGE (data not shown). As indicated in Table  2 , clonal patterns were identical for seven MRSA isolates of the southern German epidemic strain. One MRSA isolate belongs to the Hannover area epidemic strain and one MRSA strain showed a new pattern with no de¢ned clonal similarity.
Immune response of healthy adults against MRSA
In order to assess the immune response of healthy individuals against MRSA speci¢c antigens, sera of 15 healthy donors were analyzed by immunoblotting with whole cell lysate proteins of MRSA strains. The donors had no history of infection caused by MRSA. A representative immunoblot with serum gained from one healthy donor (no. K1) against MRSA is shown in Fig. 1 . A complex pattern of antibody response to a wide range of protein antigens was detected. Up to 25 immunodominant proteins were detectable depending on the investigated MRSA isolate. The majority of immunodominant proteins was between 30 and 50 kDa, especially in MRSA strains M943, M6398, M9969 and M9972. Taking together our results, four basic pattern of antibody response are distinguishable. The antibody response is almost unique against MRSA isolates : M134, M129, M943 (pattern 1); M418, M084 (pattern 2); M804, M9969, M9972 (pattern 3); and M6398 (pattern 4). Remarkably, no strong correlation between clonal type of a MRSA strain and appearance of a pattern of immunodominant proteins could be observed. The antibody response against antigens from other bacteria, such as S. carnosus or S. epidermidis (Fig. 1) was not as complex as the antibody response against MRSA strains. Similar immunoblots were also obtained with sera of other healthy individuals (data not shown).
Immune response of septic patients against MRSA
To de¢ne proteins acting as major antigens during sepsis, immunoblots with MRSA lysates were carried out using sera from ¢ve patients with MRSA sepsis. None of the patients died of septic shock. Representative immunoblotting experiments with sera of one patient (no. S4) at the onset of sepsis and 14 days after onset of sepsis are shown in Figs. 2 and 3 , respectively. At the onset of sepsis, immune response is similar to that determined for healthy individuals. The same distinction of four basic patterns of antibody response could be observed. Note the weaker antibody response to MRSA strains M134, M129, M084 and M804 compared to the immunoblot probed with sera of healthy individuals. In contrast, the pro¢le of immunodominant proteins 14 days after the onset of sepsis shows signi¢cant di¡erences. One characteristic feature is a clear enhancement of immunodominant proteins. In particular, a 29-kDa protein was identi¢ed as an abundant antigen.
Minor variations in molecular mass of this immunodominant protein were detected in preparations of MRSA strains M418, M084 and 6398. The immunodominant proteins of these strains run slightly below 29 kDa. The enhancement of antibody response to the protein of 29 kDa and the molecular size variation was recognized with all sera of septic patients (Table 2) . A second remarkable feature in immunoblots after onset of sepsis is the detection of other abundant protein antigens with apparent molecular masses of 17 and 10 kDa, respectively. The Table 3 Characterization of identi¢ed immunodominant proteins of MRSA protein antigens of 10 kDa were prominent in three of ¢ve sera from patients with sepsis and the protein antigens of 17 kDa could be observed in immunoblots of all septic patients. The antibody responses of septic patients, colonized individuals and healthy donors against the immunodominant proteins of 29 kDa, 17 kDa and 10 kDa are given in Table 2 . All immunoblots of healthy individuals showed a weak antibody response to protein of 29 kDa. A protein of 17 kDa was detected in immunoblots of seven healthy donors and was traceable in small amounts in preparations of MRSA strains M418, M943, M084, M6398 and M9972. Proteins of 10 kDa were never detected following blotting with sera of healthy individuals. Blots with sera from colonized individuals also showed variation in detection of the 29-kDa proteins. Immune response against protein of 17 kDa was not unique. Sera from two colonized individuals (Table 1 , nos. C1, C2) showed only a weak antibody response. Protein of 10 kDa was not observed in colonized individuals.
Immune response against extracellular proteins
Immunoblots of culture supernatant of MRSA strains were obtained to investigate the nature of the immunodominant proteins. Among other immunodominant antigens, the prominent protein of 29 kDa was detected in all preparations of MRSA strains with serum after the onset of sepsis of patient no. S4 (Table 1) (not shown).
Molecular analysis of immunodominant protein
According to changes of antibody response during the course of sepsis, immunodominant proteins of 29, 17 and 10 kDa were isolated and further analyzed by N-terminal amino acid sequence analysis (Fig. 4) . Interestingly, the preparation of immunodominant proteins of 10 kDa harbored two di¡erent proteins. Further sequence analysis of the 29-kDa protein in protein databases revealed 29% identity of the entire protein with secreted protein SceA precursor of S. carnosus (Table 3 ). The complete coding sequence of the protein was identi¢ed by use of the un¢nished S. aureus genome database [30] and checked by DNA sequencing. The amino acid sequence and the coding sequence was assigned to GenBank/EMBL (accession number AF144681).
Interestingly, the N-terminal amino acid sequence, which we determined by N-terminal sequencing (Fig. 4 , no. 1), matched positions 30^61 of the entire protein deduced from the DNA sequence data suggesting that the ¢rst 29 amino acids might be a protein signal sequence.
Sequence analysis of the 17-kDa protein revealed no homology to any currently known protein. The amino acids determined by N-terminal sequencing matched positions 37^65 of the putative protein deduced from DNA sequence of un¢nished S. aureus genome sequence data [30] suggesting that the ¢rst 36 amino acids of the protein form a signal sequence. The amino acid sequence of protein of 17-kDa and the corresponding DNA sequence was assigned to GenBank/EMBL (accession number AF144682). The putative functions of the proteins of 29 kDa and 17 kDa are not known. The two novel proteins were named IsaA (29 kDa) and IsaB (17 kDa), respectively. The N-terminal amino acid sequence of one protein of 10 kDa (Fig. 4, no. 3) exhibited 100% identity to phosphocarrier protein Hpr in S. aureus. The complete coding sequence of the other protein of 10 kDa was identi¢ed by use of the un¢nished S. aureus genome database [30] . The internal sequence of amino acid positions 12^45 of the protein of 10 kDa revealed 100% identity with the major cold shock protein CspA of S. aureus, recorded in protein database (NCBI Entrez Protein). According to this result the major cold shock protein CspA of S. aureus may be only partially described in the database, since the ¢rst 11 N-terminal amino acids and the last 11 C-terminal amino acids of our sequence are not recorded.
ELISA test with immunodominant proteins
The genes encoding the immunodominant antigens IsaA, IsaB, Hrp, and CspA were cloned into suitable vector systems and expressed as fusion proteins with CaM binding peptide domains. In order to con¢rm the speci¢c-ity of the antibody reactions, the recombinant staphylococcal proteins were used in ELISA assays with di¡erent patient sera. As indicated in Fig. 5 , serum from patient no. S4 (Table 1 ) obtained 14 days after onset of sepsis strongly reacted with the antigens IsaA, IsaB, Hpr and CspA. In contrast, antiserum obtained 1 day after onset of sepsis gave only weak (IsaA, IsaB) or no signal (Hpr, CspA) in the ELISA tests. These data con¢rm our ¢nding that the staphylococcal proteins IsaA, IsaB, Hrp and CspA act as strong antigens in episodes of human sepsis.
Discussion
The aim of this study was to identify immunodominant structures which are expressed in vivo during sepsis caused by MRSA. We demonstrate that human sepsis caused by MRSA leads to signi¢cant changes in antibody response against four MRSA protein antigens. Our results revealed a complex pattern of antibody response against immunodominant proteins from MRSA even in healthy individuals indicating native circulating antibodies. The ¢nding of native antibodies in healthy individuals is in agreement with previous studies concerning the antibody response against S. aureus [32, 33] . The fact that all healthy individuals mount a comprehensive and almost similar immune response to MRSA is surprising, because only 10^25% of healthy adults are colonized with S. aureus [34^36]. On the other hand, cross reactivity between S. aureus antigens and antigens of other bacterial organism has been already described [37] . Cross reactivity may be one possible explanation for the weak antibody response against immunodominant proteins of 29 kDa and 17 kDa obtained in some immunoblots with sera from healthy individuals. Detected variations in pattern of antibody response from the di¡erent healthy individuals may be due to discrimination among methicillin resistant staphylococcal strains.
By contrast, the immune response to bacteria of related species, such as S. epidermidis or S. carnosus, is not as complex as the host response against MRSA. However, the presence of native circulating antibodies throughout individuals in a normal population does not necessarily provide a strong protection from infection, since patients at the onset of sepsis also showed an immune response which is comparable to healthy individuals. In this case, not the occurrence of antibodies but rather the initial antibody titers seemed to in£uence the course of sepsis, as we show in Fig. 2 , where a weaker antibody response to some MRSA isolates was observed in comparison to healthy individuals.
Of special interest was the antibody response in patients after the onset of sepsis. It was found that patients who developed sepsis had a di¡erent antibody response compared to healthy individuals to at least four proteins. Two of these antigens are proteins with apparent molecular masses of 29 and 17 kDa. Similar ¢ndings have been described before. However, the antigens were not analyzed in detail [33, 38] . IsaA speci¢c antibodies were detected in all healthy adults, in all colonized patients as well as in patients su¡ering from sepsis. In general, the antibody response in healthy adults and colonized patients was clearly weaker than in septic patients. This might indicate that seroconversion against IsaA is an essential step in host immune defense. Most important, the IsaA protein was also detected in culture supernatant. The similarity of IsaA to secreted protein SceA precursor of S. carnosus and detection of an internal amino acid segment by Nterminal amino acid sequence analysis indicating a possible protein signal sequence are in agreement with this ¢nd-ing. IsaB, the protein of 17 kDa, was only detected in small amounts in immunoblots using sera from healthy adults and two colonized patients. Otherwise, all septic patients showed an increase in antibody response against IsaB, even patients S2, S3, and S5, with serum collected in an early stage of sepsis. Regarding this observation, antibody response against IsaA as well as antibody response against IsaB must be an early event in human sepsis.
However, the native function of IsaA and IsaB and their possible role in pathogenesis of infections due to MRSA are unknown. The other two detected immunodominant proteins are known proteins. The amino acid sequence and structural analysis of phosphocarrier protein Hpr of the phosphoenolpyruvate sugar phosphotransferase system in S. aureus have been characterized extensively [39^41] . The other protein of 10 kDa, the major cold shock protein CspA of S. aureus, has been identi¢ed recently. Contrary to our ¢ndings, the antibody response against a 10-kDa protein in a di¡erent study was presumed to be a heat shock response [42] .
It was reported that after heat shock stress the antibody response was enhanced. In this study a stronger immune response against a 10-kDa protein was induced after cold shock stress (data not shown). These results might indicate that this protein is a general stress protein. However, none of the healthy adults showed an antibody response against proteins of 10 kDa. By contrast to IsaA and IsaB, only two of ¢ve septic patients (nos. S1 and S4) had a marked antibody response against proteins of 10 kDa. Subjects without an immune response against proteins of 10 kDa were the patients with serum collected in the early stage of sepsis. It has been reported that seroconversion might require up to 14 days [43, 44] . Nevertheless, humoral immune response should be generated exclusively against cell wall or extracellular components. Cold shock protein has been suggested to be a DNA binding protein [45] and therefore a cytosolically located protein and phosphocarrier protein is thought to be bound to the inner cell membrane. By contrast, both proteins were observed after two-dimensional gel electrophoresis of extracellular proteins of MRSA (M. Hecker, unpublished data). Additionally, the surface location of phosphocarrier protein Hpr in Streptococcus suis has been reported [46] . All those data may support our ¢ndings.
This study demonstrates that human sepsis caused by MRSA results in the development of a speci¢c antibody response. Identi¢cation of at least four immunogenic proteins, where seroconversion occurs, is likely of direct clinical value. Those proteins might act as putative candidates for the development of antibody based therapy of infections caused by MRSA strains. Even if new e¡ective antibiotics are discovered, supportive antibody therapy may help to decrease the high mortality of severe staphylococcal infections.
